Medical Management of Primary Hyperparathyroidism with Concommitant Multiple Myeloma

被引:9
作者
Fanari, Zaher [1 ]
Kadikoy, Huseyin [1 ]
Haque, Waqar [1 ]
Pacha, Omar [1 ]
Abdellatif, Abdul [1 ,2 ]
机构
[1] Baylor Coll Med, Dept Med, Houston, TX 77030 USA
[2] Baylor Coll Med, Div Nephrol, Houston, TX 77030 USA
关键词
primary hyperparathyroidism; multiple myeloma; hypercalcemia; PARATHYROID ADENOMA; NPS R-568; HYPERCALCEMIA; CINACALCET; PATIENT; CALCIUM; MILD; RATS;
D O I
10.2169/internalmedicine.49.2705
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Primary hyperparathyroidism (PHPT) and multiple myeloma (MM) are frequently observed in the adult population and can each independently lead to hypercalcemia. Despite the frequency of hypercalcemia secondary to PHPT and MM, these two conditions only rarely concurrently present in patients. We describe the management of PHPT in the setting of poorly differentiated MM in a patient presenting with hypercalcemia and pancytopenia. The patient was deemed at increased risk for surgical removal of the parathyroid gland and refused surgical intervention, so we chronically managed her PHPT and hypercalcemia with Cinacalcet and bisphosphonates. All of the similar cases in the literature are reviewed in this report along with medical management of PHPT. We believe that we describe the first medically managed PHPT in the setting of MM.
引用
收藏
页码:581 / 584
页数:4
相关论文
共 22 条
[1]  
Chisholm R C, 1981, J Natl Med Assoc, V73, P875
[2]   REFRACTORY HYPERCALCEMIA - PARATHYROID ADENOMA OR MULTIPLE-MYELOMA [J].
DALGLEISH, AG ;
GATENBY, PA .
MEDICAL JOURNAL OF AUSTRALIA, 1984, 140 (02) :99-100
[3]   Cinacalcet: An oral calcimimetic agent for the management of hyperparathyroidism [J].
Dong, BJ .
CLINICAL THERAPEUTICS, 2005, 27 (11) :1725-1751
[4]   Bisphosphonates: Mechanism of action and role in clinical practice [J].
Drake, Mathew T. ;
Clarke, Bart L. ;
Khosla, Sundeep .
MAYO CLINIC PROCEEDINGS, 2008, 83 (09) :1032-1045
[5]   The calcimimetic NPS R-568 decreases plasma PTH in rats with mild and severe renal or dietary secondary hyperparathyroidism [J].
Fox, J ;
Lowe, SH ;
Conklin, RL ;
Nemeth, EF .
ENDOCRINE, 1999, 10 (02) :97-103
[6]  
Fox J, 1999, J PHARMACOL EXP THER, V290, P473
[7]   HYPERCALCEMIA DUE TO THE COEXISTENCE OF PARATHYROID ADENOMA AND MYELOMATOSIS [J].
FRANCIS, RM ;
BYNOE, AG ;
GRAY, C .
JOURNAL OF CLINICAL PATHOLOGY, 1982, 35 (07) :732-736
[8]   PRIMARY HYPERPARATHYROIDISM ASSOCIATED WITH MULTIPLE-MYELOMA [J].
GOTO, S ;
YOSHIOKA, M ;
NAGAI, K ;
ABE, A ;
MURAKAWA, E ;
YAMAZAKI, N ;
KOYAMA, T ;
SEKIYA, M .
INTERNAL MEDICINE, 1995, 34 (10) :988-991
[9]   PRIMARY HYPERPARATHYROIDISM COMPLICATED BY MULTIPLE-MYELOMA [J].
HOELZER, DR ;
SILVERBERG, AB .
ARCHIVES OF INTERNAL MEDICINE, 1984, 144 (10) :2069-2071
[10]   PARATHYROID ADENOMA IN A PATIENT WITH MULTIPLE-MYELOMA [J].
JACKSON, RM ;
ORLAND, MJ .
SOUTHERN MEDICAL JOURNAL, 1979, 72 (10) :1336-1337